News & Events Archives - Page 17 of 21

Artificial Intelligence Solutions for Cardiovascular Disease Detection and Management in Women

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Artificial intelligence (AI) is a method of data analysis that enables machines to learn patterns from datasets and make predictions. With advances in computer chip technology for data processing and the increasing availability of big data, AI can be leveraged to improve cardiovascular care for women – an often understudied and undertreated population. The authors of this article briefly discuss the potential benefits of AI-based solutions in cardiovascular care for women and also highlight inadvertent drawbacks to the use of AI and novel digital technologies in women.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0024

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Wendy Tatiana Garzon-Siatoya, Andrea Carolina Morales-Lara and Demilade Adedinsewo. Artificial Intelligence Solutions for Cardiovascular Disease Detection and Management in Women: Promise and Perils. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0024

Angiography-Derived Fractional Flow Reserve in Coronary Assessment: Current Developments and Future Perspectives

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Coronary physiology assessment is an important factor in guiding myocardial revascularization. A growing body of research highlights the value of using fractional flow reserve, FFR and other pressure-based indicators for functional assessment of stable coronary stenoses. Invasive functional coronary assessment techniques have evolved from intracoronary wire-based to wire-free approaches as a result of technological advancements. In addition, several software programs on the market have been thoroughly investigated and validated against invasive FFR, and have shown good accuracy and correlation. However, use of FFR remains modest.

This article provides an overview of angiography-based FFR solutions and compares their technologies. Additionally, a systematic scoping review was performed to understand the research landscape in wire-free coronary physiology assessment, to complement the narratives of existing FFR trials on wire-free FFR. Furthermore, future developments and strategies that could expand the use of wire-free computed coronary functional assessment in the Asia Pacific region are discussed.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0021

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Han Bing Chow, Shirley Siang Ning Tan and Wei Hong Lai et al. Angiography-Derived Fractional Flow Reserve in Coronary Assessment: Current Developments and Future Perspectives. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0021

Integration Analysis of Epigenetic-related m 6A-SNPs Associated with Atrial Fibrillation

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Numerous single nucleotide polymorphisms (SNPs) have been identified as genetic contributors to atrial fibrillation (AF). The aim of this study was to investigate the effects of genome-wide N⁶-methyladenosine (m⁶A)-SNPs on AF.

m⁶A-SNPs were identified by analysis of raw data from published AF GWAS datasets and the list of m⁶A-SNPs from the m⁶AVar database. Expression quantitative trait loci (eQTL) analysis was conducted to evaluate the effects of m⁶A-SNPs on gene expression. The expression of linked genes was validated in three independent AF-associated gene expression datasets (GSE14975, GSE108660 and GSE2240).

A total of 1429 (6.2%) unique m⁶A-SNPs that were significantly associated with AF were identified. Seventeen m⁶A-SNPs in 14 genes reached genome-wide significance. Eight m⁶A-SNPs demonstrated eQTL signals. Four m⁶A-SNPs (rs383692, rs3211105, rs1061259 and rs1152582) exhibited strong cis-eQTL signals associated with the gene expression levels of SMIM8, JMJD1C and SYNE2. SYNE2 and SMIM8 had differential gene expression levels between the AF and sinus rhythm groups. In addition, SYNE2 expression was uniformly downregulated in AF samples compared with normal control samples in the three datasets.

The results provide the first demonstration that m⁶A-SNPs are strongly associated with AF, and extend understanding of m⁶A modification as a potential biological pathway underlying AF.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0022

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Zhenhong Jiang, Xin Liu and Jianping Hu et al. Integration Analysis of Epigenetic-related m6A-SNPs Associated with Atrial Fibrillation. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0022

Inhibition of Stimulator of Interferon Genes Protects Against Myocardial Ischemia-Reperfusion Injury in Diabetic Mice

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Although the past decade has witnessed substantial scientific progress with the advent of cardioprotective pharmacological agents, most have failed to protect against myocardial ischemia/reperfusion (I/R) injury in diabetic hearts. This article investigates the role of stimulator of interferon genes (STING) in I/R injury in diabetic mice and further exploring the underlying mechanisms.

Type 2 diabetic mice were subjected to I/R or sham operation to investigate the role of STING. STING knockout mice were subjected to 30 minutes of ischemia followed by reperfusion for 24 hours. Finally, myocardial injury, cardiac function, and inflammation levels were assessed.

STING pathway activation was observed in diabetic I/R hearts, as evidenced by increased p-TBK and p-IRF3 expression. STING knockout significantly decreased the ischemic area and improved cardiac function after I/R in diabetic mice. STING knockout also elicited cardio-protective effects by decreasing serum cardiac troponin T and lactate dehydrogenase levels, thus diminishing the inflammatory response in the heart after I/R in diabetic mice. In vitro, STING inhibition decreased the expression of hypoxia-re-oxygenation-induced inflammatory cytokines.

Targeting STING inhibits inflammation and prevents I/R injury in diabetic mice. Thus, STING may be a potential novel therapeutic target against myocardial I/R injury in diabetes.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0020

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yuce Peng, Guoxiang Zhou and Mingyu Guo et al. Inhibition of Stimulator of Interferon Genes Protects Against Myocardial Ischemia-Reperfusion Injury in Diabetic Mice. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0020

Expression Patterns and Functions of Cardiac Pigment Epithelium-Derived Factor During Cardiac Development

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This paper describes the expression profiles and roles of cardiac pigment epithelium-derived factor (PEDF) during cardiac development. Gene datasets from the Gene Expression Omnibus (GEO) database were used to analyze the correlation between cardiac PEDF expression and heart disease. Western blotting, immunohistochemistry, histological staining and echocardiography were used to assess the expression patterns and functions of PEDF during cardiac development.

Analysis of GEO data sets indicated that the expression of cardiac PEDF correlated with the occurrence and development of various heart diseases. Western blotting of various tissues in mice at 30 postnatal days of age indicated higher PEDF expression in the heart and aorta than the liver. Immunohistochemical results demonstrated that the expression of cardiac PEDF significantly decreased after birth, mainly because of a significant decrease in PEDF expression in the cytoplasm. Histological staining and echocardiography indicated that PEDF deficiency had no significant effects on cardiac structure, cardiac function and vascular hemodynamics in 8-week-old mice.

Cardiac PEDF shows high expression and dynamic changes during cardiac development, but has no effects on cardiac structure, function and vascular hemodynamics.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0015#aff2

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Xing-hui Li, Yan-di Wu and Tong-sheng Huang et al. Expression Patterns and Functions of Cardiac Pigment Epithelium-Derived Factor During Cardiac Development. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0015

Sex Differences in Quality of Life and their Explanatory Variables in Patients with Non-Valvular Atrial Fibrillation

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Women with atrial fibrillation (AF) have poorer quality of life (QoL) than men; however, the factors contributing to the poorer QoL in women is unclear.

The authors of this article analyzed data for 3562 patients with non-valvular AF enrolled in the China Registry of Atrial Fibrillation. The Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) was used to evaluate QoL, which was compared between women and men. A multivariate logistic regression analysis model was used to explore factors potentially explaining the sex difference in QoL.

Overall, 43.3% of the cohort comprised women (n=1541) who were older than their male counterparts (72 ± 9.8 vs. 68 ± 11.9 years, P<0.001). Compared with men, women were more likely to have more symptoms, hypertension, diabetes mellitus, and heart failure. Women were less likely than men to receive catheter ablation (4.5% vs. 6.1%, P=0.044). Women also had lower physical component summary (PCS) scores (48 ± 9 vs. 51 ± 9, P<0.001) and mental component summary (MCS) scores (49 ± 10 vs. 51 ± 10, P<0.001) than men. In the multivariable analysis of the poorer PCS scores in women, patient age explained 32.9%, low socioeconomic status explained 20.0%, lifestyle explained 14.3%, cardiovascular comorbidities explained 15.7%, the presence of more symptoms explained 5.7%, and less catheter ablation explained 1.4%. These factors also explained similar proportions of the sex difference in MCS scores. Together, these factors explained 54.3% of the poorer physical function status and 46.8% of the poorer mental function status in women than men.

Women with AF had poorer QoL than men. The following factors partly explained the poorer QoL in women: older age, low level of socioeconomic status, more cardiovascular comorbidities, less smoking and drinking, more symptoms, and less catheter ablation.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0017

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Qing Li, Yinong Chen and Luyao Yu et al. Sex Differences in Quality of Life and their Explanatory Variables in Patients with Non-Valvular Atrial Fibrillation. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0017

Identifying Key Genes and Related Molecules as Potential Biomarkers in Human Dilated Cardiomyopathy by Comprehensive Bioinformatics Analysis

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Dilated cardiomyopathy (DCM) is a non-ischemic heart disease that poses a substantial global health burden, but its underlying molecular mechanisms remain poorly understood.

Weighted gene co-expression network analysis, differential expression analysis of genes, enriched analysis and LASSO model construction were performed in R software. miRWalk 2.0 and StarBase v2.0 were used to predict the target miRNAs and circRNAs of hub genes, respectively.

Four hub genes (COL3A1, COL1A2, LUM and THBS4) were identified, which were significantly enriched in fibrosis pathways, including extracellular matrix, biological process, and the TGF beta signaling and focal adhesion pathways. The LASSO model accurately predicted the occurrence of DCM. Additionally, three miRNAs (hsa-let-7b-5p, hsa-let-7c-5p and hsa-miR-29b-3p) and 30 circRNAs (including GIT2_hsa_circRNA10114, ANKRD52_hsa_circRNA9983 and JARID2_hsa_circRNA6618) were found to be associated with DCM.

Bioinformatics analysis identified hub genes and related molecules that may be highly associated with DCM. These findings provide insights into potential targets for improving diagnosis and pharmacological therapies to prevent DCM progression.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0018

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yingrui Li, Jianlin Du and Bin Liu et al. Identifying Key Genes and Related Molecules as Potential Biomarkers in Human Dilated Cardiomyopathy by Comprehensive Bioinformatics Analysis. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0018

Call for Papers: Cardiovascular Innovations and Applications

The Co-Editors-in-Chief of Cardiovascular Innovations and Applications (CVIA), Jamie B. Conti, University of Florida, Gainesville, FL, USA and Jianzeng Dong, Beijing Anzhen Hospital, Capital Medical University, Beijing, China invite you to submit an article to the journal.

Cardiovascular Innovations and Applications (CVIA) seeks to publish focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification.

CVIA was launched in 2015 as an open access journal, offering high visibility and discoverability through its open access publishing approach. As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, CVIA will actively support authors through open access publishing and through waiving of author fees.

The journal welcomes the following article types:

Editorials
Original Research
Review Articles
Commentaries
Case Reports
Case Studies
Methodology papers related to clinical trials
Letters to the Editor

Benefits of choosing CVIA for your research

CVIA is an open access journal which means that your paper is available to anyone in the world to download for free directly from the ScienceOpen website.
Unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
No Author submission or article processing charges.
Authors can retain the copyright to their article.
Fast peer review.
Fast publication online after article acceptance.
Professional/global marketing/promotion of your articles. Articles are:

Sent to clinicians and researchers in the cardiovascular community through email alerts;
Promoted to the Journal followers on Twitter and Facebook;
Distributed to news outlets through press releases.

For more information on our journal please see the CVIA website https://cvia-journal.org/; recently published content is available on ScienceOpen https://www.scienceopen.com/search#collection/32b77252-732d-468f-a6f9-9637d4762967 .

Submissions to Cardiovascular Innovations and Applications (CVIA) can be made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/cvia-journal. There are no author submission or article processing fees.

Articles of interest include:

Psychosocial Risk Factors and Cardiovascular Disease: Epidemiology, Screening, and Treatment Considerations

Novel SPECT Technologies and Approaches in Cardiac Imaging

Global Burden of Cardiovascular Disease

Clinical Characteristics and Durations of Hospitalized Patients with COVID-19 in Beijing: A Retrospective Cohort Study

Rationale and Design of the Randomized Controlled Trial of Intensive Versus Usual ECG Screening for Atrial Fibrillation in Elderly Chinese by an Automated ECG System in Community Health Centers in Shanghai (AF-CATCH)

The Effect of Home-Based Cardiac Rehabilitation on Functional Capacity, Behavior, and Risk Factors in Patients with Acute Coronary Syndrome in China

Current Management Strategies in Patients with Heart Failure and Atrial Fibrillation: A Review of the Literature

Telemedicine: Its Importance in Cardiology Practice. Experience in Chile

The Relationship Between Mean Platelet Volume and In-Hospital Mortality in Geriatric Patients with ST Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention

Management of Hypertension: JNC 8 and Beyond

CVIA is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life, CNKI Scholar (Chinese National Knowledge Infrastructure) and Ulrich’s web Databases.

Follow CVIA

Twitter @CVIA_Journal

Facebook https://www.facebook.com/cvia.journal/

Five-Year Clinical Outcomes After XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) Implantation

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at evaluating 5-year effectiveness and safety in participants after XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) implantation.

From December 2013 to May 2014, 108 patients (127 lesions) were treated with the XIENCE PRIME EECSS. The entire follow-up included annual assessments for 5 years after treatment or until one of the clinical endpoints was reached. We evaluated the 5-year clinical outcomes with Kaplan-Meier analysis and the Cox regression model.

Nearly three-quarters of the participants were men (76.8%), and the average age was 65.6 ± 10.8 years. Bifurcation lesions accounted for 96.1% (122 lesions), and left main lesions accounted for 3.9% (five lesions), with a total count of 127 lesions. The cumulative rate of major adverse cardiac events was as follows: 1 year, 1.9%; 2 year, 4.0%; and 5 year, 10.0%. No definite or probable stent thrombosis was observed, and the rate of target lesion failure was only 3.3% over 5 years. The cumulative rate of major bleeding eventually increased to only 4.4%.

The 5-year clinical outcomes were favorable in patients treated with XIENCE PRIME EECSS, and the incidence of stent thrombosis and target lesion failure was relatively low. The incidence of major bleeding gradually increased but remained moderate.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0013

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Rongrong Shen, Peiyu Zhang and Jing Liu et al. Five-Year Clinical Outcomes After XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) Implantation. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0013

Advances in the Application of Pulsed Field Ablation for Arrhythmia Treatment

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The increased application of catheter ablation to treat cardiac arrhythmias has contributed to continued exploration of safe and effective tissue ablation tools in the field of electrophysiology. Pulsed field ablation (PFA), a novel recently developed non-thermal energy-based technique, uses trains of microsecond duration high-amplitude pulses to ablate target cells. Several preclinical and clinical studies have demonstrated that PFA is a promising tool for cardiac ablation to treat arrhythmia. In addition to being an effective tissue ablation technique, PFA is safe, because it avoids damage to the surrounding cells/tissues. This article focuses on efficacy and safety outcomes reported in preclinical and clinical studies evaluating the effects of PFA on arrhythmia, and discusses limitations and potential future directions of PFA.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0019

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Fuding Guo, Jun Wang and Liping Zhou et al. Advances in the Application of Pulsed Field Ablation for Arrhythmia Treatment. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0019

CVIA Journal

Category: News & Events